Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NEVRO CORP (NVRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/01/2023 8-K Quarterly results
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/30/2023 8-K Appointed a new director
04/26/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
01/09/2023 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance Company Announces 2023 Retirement Plans of D. Keith Grossman from Positions of CEO and President; Will Remain as Chairman of the Board Company to Present Today at J.P. Morgan Healthcare Conference at 3:45 pm Pacific Time REDWOOD CITY, California – January 9, 2023 – Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth quarter and full-year 2022 revenue results. The company also provided full-year 2023 revenue guidance and announced its Chief Executive Officer and President, D. Keith Grossman, has informed the Board of his intention t..."
11/02/2022 8-K Quarterly results
09/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/03/2022 8-K Quarterly results
Docs: "Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance"
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes"
05/31/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
02/23/2022 8-K Quarterly results
Docs: "Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance"
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million"
11/08/2021 8-K Quarterly results
Docs: "Vice President, Investor Relations"
08/31/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
07/19/2021 8-K Quarterly results
Docs: "www.HFXforPDN.com"
05/28/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/03/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Nevro Announces Director Appointment Industry Veteran Sue Siegel Joins the Board Founding Investor and Longtime Director Wilfred Jaeger Steps Down"
11/05/2020 8-K Quarterly results
Docs: "Nevro Corp. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019"
08/05/2020 8-K Quarterly results
06/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/26/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/05/2020 8-K Quarterly results
04/13/2020 8-K Other Events  Interactive Data
04/07/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Underwriting Agreement, by and between Nevro Corp. and Morgan Stanley & Co. LLC, related to the Common Stock",
"Underwriting Agreement, by and between Nevro Corp. and Morgan Stanley & Co. LLC, related to the Notes",
"Supplemental Indenture, by and between Nevro Corp. and Wilmington Trust, National Association, as Trustee",
"Opinion of Latham & Watkins LLP related to the Common Stock",
"Opinion of Latham & Watkins LLP related to the Notes",
"Letter Agreement, between Goldman Sachs & Co. LLC and Nevro Corp., regarding the Base Warrants",
"Letter Agreement, between Goldman Sachs & Co. LLC and Nevro Corp., regarding the Base Call Option Transaction",
"Letter Agreement, between Morgan Stanley & Co. International plc and Nevro Corp., regarding the Base Warrants",
"Letter Agreement, between Morgan Stanley & Co. International plc and Nevro Corp., regarding the Base Call Option Transaction",
"Letter Agreement, between Goldman Sachs & Co. LLC and Nevro Corp., regarding the Additional Call Option Transaction"
04/01/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Nevro Provides First Quarter and FY2020 Update Preliminary Unaudited First Quarter 2020 Worldwide Revenue Expected to be $86.4-$86.9 Million Company Withdraws FY2020 Guidance Due to COVID-19 Impact REDWOOD CITY, Calif., April 1, 2020 - Nevro Corp. , a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced preliminary unaudited worldwide revenue for the quarter ended March 31, 2020 and the withdrawal of its full year 2020 financial guidance issued on February 25, 2020. In addition, the Company provided an update on the actions it is taking in response to the COVID-19 pandemic. First Quarter 2020 Update Preliminary unaudited first quarter 2020 worldwide revenue is expected to be in the range of $86.4 to $86.9 mi..."
02/28/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
01/14/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Nevro Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue Company Provides Revenue Guidance for 2020"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy